| Challenges in diabetes management in Indonesia: a literature review P Soewondo, A Ferrario, DL Tahapary Globalization and health 9, 1-17, 2013 | 314 | 2013 |
| Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden A Ferrario, P Kanavos Social science & medicine 124, 39-47, 2015 | 209 | 2015 |
| How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries S Vogler, V Paris, A Ferrario, VJ Wirtz, K de Joncheere, P Schneider, ... Applied health economics and health policy 15, 307-321, 2017 | 201 | 2017 |
| The economic burden of diabetes in India: a review of the literature CAK Yesudian, M Grepstad, E Visintin, A Ferrario Globalization and health 10, 1-18, 2014 | 198 | 2014 |
| Barriers for access to new medicines: searching for the balance between rising costs and limited budgets B Godman, A Bucsics, P Vella Bonanno, W Oortwijn, CC Rothe, A Ferrario, ... Frontiers in Public Health 6, 328, 2018 | 182 | 2018 |
| Managed entry agreements for pharmaceuticals: the European experience A Ferrario, P Kanavos EMINet, 2013 | 182 | 2013 |
| The implementation of managed entry agreements in Central and Eastern Europe: findings and implications A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ... Pharmacoeconomics 35, 1271-1285, 2017 | 170 | 2017 |
| Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review AD Bertoldi, P Kanavos, GVA França, A Carraro, CAO Tejada, PC Hallal, ... Globalization and health 9, 1-12, 2013 | 167 | 2013 |
| Diabetes management in Thailand: a literature review of the burden, costs, and outcomes C Deerochanawong, A Ferrario Globalization and Health 9, 1-18, 2013 | 146 | 2013 |
| Personalizing health care: feasibility and future implications B Godman, AE Finlayson, PK Cheema, E Zebedin-Brandl, ... BMC medicine 11, 1-23, 2013 | 129 | 2013 |
| Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs P Kanavos, A Ferrario, S Vandoros, GF Anderson Health affairs 32 (4), 753-761, 2013 | 126 | 2013 |
| Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs RE Malmström, BB Godman, E Diogene, C Baumgärtel, M Bennie, ... Frontiers in pharmacology 4, 39, 2013 | 119 | 2013 |
| Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications MM Nashilongo, B Singu, F Kalemeera, M Mubita, E Naikaku, A Baker, ... Cardiovascular drugs and therapy 31, 565-578, 2017 | 103 | 2017 |
| Managing risk and uncertainty in health technology introduction: the role of managed entry agreements P Kanavos, A Ferrario, G Tafuri, P Siviero Global Policy 8, 84-92, 2017 | 79 | 2017 |
| Challenges in diabetes mellitus type 2 management in Nepal: a literature review B Gyawali, A Ferrario, E van Teijlingen, P Kallestrup Global health action 9 (1), 31704, 2016 | 70 | 2016 |
| Diabetes in Algeria and challenges for health policy: a literature review of prevalence, cost, management and outcomes of diabetes and its complications L Lamri, E Gripiotis, A Ferrario Globalization and health 10, 1-14, 2014 | 65 | 2014 |
| Proposal for a regulation on health technology assessment in Europe–opinions of policy makers, payers and academics from the field of HTA P Vella Bonanno, A Bucsics, S Simoens, AP Martin, W Oortwijn, ... Expert review of pharmacoeconomics & outcomes research 19 (3), 251-261, 2019 | 51 | 2019 |
| Drug promotional activities in Nigeria: impact on the prescribing patterns and practices of medical practitioners and the implications JO Fadare, KA Oshikoya, OO Ogunleye, OO Desalu, A Ferrario, ... Hospital practice 46 (2), 77-87, 2018 | 50 | 2018 |
| Strategies to achieve fairer prices for generic and biosimilar medicines A Ferrario, G Dedet, T Humbert, S Vogler, F Suleman, HB Pedersen bmj 368, 2020 | 49 | 2020 |
| Global access to quality-assured medical products: the Oxford statement and call to action PN Newton, KC Bond, P Newton, K Bond, V Abiola, K Ade-Abolade, ... The Lancet Global Health 7 (12), e1609-e1611, 2019 | 38 | 2019 |
